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Abstract
High rates of tuberculosis transmission are driving the ongoing global tuberculosis epidemic, and 
there is a pressing need for research focused on understanding and, ultimately, halting 
transmission. The ongoing tuberculosis–human immunodeficiency virus (HIV) coepidemic and 
rising rates of drug-resistant tuberculosis in parts of the world add further urgency to this work. 
Success in this research will require a concerted, multidisciplinary effort on the part of 
tuberculosis scientists, clinicians, programs, and funders and must span the research spectrum 
from biomedical sciences to the social sciences, public health, epidemiology, cost-effectiveness 
analyses, and operations research. Heterogeneity of tuberculosis disease, both among individual 
patients and among communities, poses a substantial challenge to efforts to interrupt transmission. 
As such, it is likely that effective interventions to stop transmission will require a combination of 
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approaches that will vary across different epidemiologic settings. This research roadmap 
summarizes key gaps in our current understanding of transmission, as laid out in the preceding 
articles in this series. We also hope that it will be a call to action for the global tuberculosis 
community to make a sustained commitment to tuberculosis transmission science. Halting 
transmission today is an essential step on the path to end tuberculosis tomorrow.
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GETTING TO ZERO REQUIRES INTERRUPTING TRANSMISSION TODAY
With the release of the most recent Global Plan to Stop tuberculosis, the attention and efforts 
of the global tuberculosis community are rightly focused on the necessary goal to end 
tuberculosis [1]. Achieving this ambitious goal will not be easy. Tuberculosis, often called 
the oldest disease of mankind, is now the leading global killer among infectious diseases and 
the leading cause of death for people with HIV [2, 3]. Rising rates of drug resistance in parts 
of the world bring further urgency to the imperative to end tuberculosis because each case of 
drug resistance is orders of magnitude more difficult to treat with second- and third-line drug 
regimens that are more costly for tuberculosis programs, more toxic for patients, and often 
less effective [4]. The Global Plan calls for a paradigm shift in our approach to combating 
tuberculosis, including a change in mindset whereby tuberculosis has no place in our 
societies— with a push for more patient-centered care, programmatic innovations, and 
sustained increases in funding. Yet a critical component of what will be necessary for 
success has been too often neglected: an explicit focus on halting transmission.
The analogy of “turning off the tap” of new tuberculosis cases is often upheld as key for 
decreasing the global burden of tuberculosis [5]; yet our ability to stop new cases hinges 
directly on our capacity to halt transmission. As with so much of tuberculosis care, our 
current tools for halting transmission have been around for decades: active case finding, 
contact investigations, and targeted testing and treatment of latent tuberculosis infection. 
These interventions have proven quite successful in decreasing the tuberculosis burden at the 
population level in key historical trials [6–8]. However, as illustrated by several large-scale 
community-based studies, implementation of these measures in modern high-burden settings 
is often challenging— and, without substantial scale-up of existing interventions and the 
addition of novel tools, it is unlikely that we will achieve the goal of ending tuberculosis in 
those areas [9–12]. For example, in sub-Saharan Africa, transmission in the community is 
often so intense that household members and other known contacts only account for a 
minority of transmission events [13–17]. As a result, contact investigation is unlikely to halt 
tuberculosis transmission on its own in higher-burden contexts, even though it may still avert 
a high absolute number of transmission events. Additional gaps in our understanding of the 
biology and local determinants of transmission underscore just how little we know about 
transmission—and how that ignorance may be undermining our efforts to end tuberculosis.
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Although others have advocated for halting transmission [18–22], we believe that this series 
offers a necessary perspective by focusing on transmission as a unique scientific discipline. 
While we must continue to deploy tools that are currently available and maximize the benefit 
from interventions that are known to be effective, we must also mobilize to develop new 
tools for combating transmission—new tools to understand where, how, and between whom 
transmission is happening. A roadmap for tuberculosis transmission research will enable us 
to track the most efficient and effective pathways for studying, understanding, and, 
ultimately, halting tuberculosis transmission. Only by focusing on transmission as both a 
sentinel event and an outcome of interest can we become proactive, rather than reactive, to 
new cases of tuberculosis. The roadmap herein draws from the articles in this series to chart 
an initial research path across the spectrum of basic sciences to applied and operations 
research. We hope that this roadmap provides tuberculosis researchers, programmers, policy 
makers, funders, and advocates with a forecast of research needs and a means for charting 
progress against milestones. Advances in transmission science will provide us with the 
necessary means for interrupting transmission wherever it may be occurring. Only then will 
we be able to design effective biomedical and sociobehavioral interventions to truly turn off 
the tap.
CURRENT TRANSMISSION RESEARCH NEEDS
In this section, we review and highlight some of the key points from the 3 scientific articles 
in this series. Within each research area—infectiousness and susceptibility, drivers of 
tuberculosis transmission, and interventions to halt the transmission of tuberculosis—we 
have emphasized gaps in our knowledge of transmission science that present immediate 
opportunities for high-impact research.
Infectiousness and Susceptibility
Multiple gaps remain in our understanding of source case infectiousness, aerosolization and 
airborne survival of Mycobacterium tuberculosis (Mtb), and host susceptibility. Source case 
infectiousness may be influenced by a number of individual-level factors, including disease 
site, sex, ethnicity, HIV status, and social risk factors [23–25]. Yet our ability to account for 
transmission being driven by each of these factors is limited. Furthermore, it is not yet 
known how subclinical disease or fluctuations in respiratory symptoms might contribute to 
transmission [26, 27]; nor is it known how variability in respiratory mechanics, tidal 
breathing, nocturnal breathing, or cough impact the likelihood of producing droplet nuclei 
with viable Mtb [28–30].
Although it is possible that pathogen-level characteristics, such as organism phenotype or 
lineage, might affect the aerobiology of tuberculosis, the role of shear forces and air and 
fluid dynamics is also likely to be quite important for aerosol transmission [29]. Once Mtb is 
released into the air, it remains unclear what proportion of droplet nuclei contain viable 
bacilli, how long those bacilli remain viable in the open environment, and whether there are 
differences between aerosolized versus alveolar Mtb [31, 32]. Elucidating the nature of 
tuberculosis transmission events by studying patient aerosols, also known as aerobiology, 
will address critical questions about the physiology and metabolic state of aerosolized Mtb, 
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the viability and persistence of infectious aerosols, and the key characteristics associated 
with infectiousness.
Once Mtb is aerosolized in an indoor environment, multiple infection control interventions 
that reduce exposure and inhalation (“environmental controls”) have been shown to be 
effective, including natural or mechanical ventilation and upper room ultraviolet germicidal 
irradiation [33]. Reducing crowding in hospital and clinic waiting areas will further limit the 
effective contact rate between infectious persons and potentially susceptible contacts [34]. 
Yet, cost of installation, logistics of maintenance, and practical considerations (eg, climate 
that precludes opening doors and windows) often present barriers to implementation of 
environmental controls. Innovations are needed that simplify and reduce costs of healthcare 
facility redesign, with monitoring of airborne infectious particles, alerts when they above a 
critical level, and direct “cleansing” of shared air.
The determinants behind the probability of aerosol deposition of Mtb in a susceptible host 
are yet another unknown. There are a number of recent efforts to characterize cough aerosol 
production and exposure, but there is no current standard for determining whether a 
particular individual was exposed to Mtb. For close contacts of tuberculosis patients with a 
negative tuberculin skin test (TST) or interferon-gamma release assay (IGRA), there is no 
way to know whether they were indeed “adequately” exposed to Mtb, whether they had 
successful “early clearance” without mounting a T-cell–mediated adaptive immune response, 
or whether they are simply anergic with a false-negative TST or IGRA. This inability to 
characterize and quantify recent exposure, including among animal models, poses a 
substantial impediment to studies of transmission and transmissibility. Efforts to offset host 
vulnerability and enhance selective immune responses may prove critical for the design of a 
tuberculosis vaccine that is capable of preventing infection and not simply diminishing 
bacterial burden.
Drivers of Tuberculosis Transmission—Know Your Epidemic, Know Your Intervention
Mounting evidence from high tuberculosis burden countries, with varying levels of HIV and 
drug-resistant tuberculosis, implicate ongoing transmission as the driving force maintaining 
high levels of tuberculosis incidence [17, 35, 36]. Drivers of transmission can be conceived 
of as 3 stages along a cascade of transmission: (1) contact between infectious and 
susceptible individuals; (2) infectiousness of a particular individual; and (3) susceptibility to 
disease of exposed individuals [22]. These stages are heterogeneous at regional and national 
levels, and the relative role of each stage is heavily dictated by local attributes, including 
access to health care, population age structure, housing, population density, and migration 
[37, 38]. Variations in individual host susceptibility, in line with the local prevalence of HIV, 
malnutrition and low body mass index, diabetes mellitus, tobacco use, alcoholism, and 
silicosis, can also dramatically alter the transmission cascade [39, 40]. The strength of local 
tuberculosis control programs’ case finding and treatment strategies is yet another factor that 
can affect local transmission dynamics; a larger proportion of undiagnosed or untreated 
patients will contribute to ongoing transmission in a community. This heterogeneity of 
transmission poses a substantial challenge to tuberculosis control. To design efficacious and 
efficient tuberculosis control strategies, it will be necessary to delineate the relative 
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contribution of the various drivers of tuberculosis in different settings. Ultimately, drivers of 
transmission must be studied and understood on a local level.
At present, measuring levels of tuberculosis transmission is also exceedingly difficult. The 
natural history and long latency period of tuberculosis means that observed cases of disease 
reflect a mix of recent transmission and reactivation disease from a remote infection. In 
addition, most cases observed through passive case-finding systems underestimate the 
number of undiagnosed, but diagnosable, infectious individuals in the community. Current 
methods to measure transmission include examining case notification rates and trends in 
TST or IGRA. However, real-time, definitive diagnosis of recent exposure to Mtb at the 
individual level is not possible with any of the currently available tests (eg, TST, IGRA, 
chest X-ray, sputum analysis). Yet there are several recent reports of promising new 
approaches to identifying recent exposure, including a T-cell immune signature capable of 
differentiating recent from remote tuberculosis infection and a blood transcriptomic 
signature associated with greater risk of progression to active tuberculosis disease [41, 42]. 
Although these signatures need to be validated in other settings, this type of biomarker of 
recent exposure would enable precisely targeted preventive therapy (akin to ring 
prophylaxis) and accelerate identification of tuberculosis “hotspots”—areas of high 
tuberculosis incidence—for earlier and more effective implementation of infection control 
measures [43]. Such hotspot detection and elimination represents a stop-gap measure to 
interrupt transmission and reduce the global burden of tuberculosis while new drugs, 
diagnostics, and vaccines are progressing through the product development pipeline. These 
hotspot communities could also serve as priority areas for piloting new transmission 
interventions as they become available [44].
More recently, molecular epidemiology using whole genome sequencing has greatly 
facilitated studies of patient-and population-level transmission [13, 14]. Interestingly, in a 
number of studies that used genotyping in the late 1990s and early 2000s, cases with genetic 
links often did not have traditional epidemiologic links [16]. Several studies have aimed to 
estimate the proportion of transmission that occurs within households by comparing 
genotypes of cases occurring within households or community settings. These studies have 
found that in medium and high tuberculosis burden settings, the majority of tuberculosis 
transmission occurs outside of households or known close contacts [15, 45]. As such, 
although contact investigations remain a critical component of any effort to identify and 
eliminate tuberculosis in the community, the proportion of tuberculosis transmission that can 
be halted through contact investigations alone may be lower in some settings than 
traditionally anticipated [46]. Furthermore, the location where infections are occurring 
within these communities remains a major unknown in the transmission ecology of 
tuberculosis. Congregate locations that facilitate air exchange between infectious cases with 
noninfected individuals, such as in transport hubs, school classrooms, and prisons, have been 
implicated as hotspots of transmission and may offer opportunities for targeted interventions 
[47, 48]. However, it is unknown whether other, less obvious sites of congregation may also 
be driving ongoing transmission. An integrated approach that combines traditional 
epidemiology with methods drawn from spatial, demographic, network, and whole genome 
analysis will undoubtedly be required to identify such drivers.
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Interventions to Halt the Transmission of Tuberculosis
Ultimately, it is not simply enough to understand where and how tuberculosis transmission 
occurs; we must intervene to interrupt that transmission if we hope to have an impact on 
incidence. To be effective in this effort, it is critical to understand which interventions, 
implemented in what fashion, are most likely to avert the largest proportion of transmission 
events (specifically, those events that result in secondary cases of infectious tuberculosis) at 
the population level. For example, in settings where transmission originates largely from 
specific and identifiable populations (eg, young adult men [49]), it may be feasible to target 
case-finding efforts at those groups. Where reactivation is common in high-risk groups (eg, 
HIV-positive individuals [50], people with risk factors such as diabetes or malnutrition [51], 
elderly populations [52]), it may be critical to target preventive therapy to those populations. 
In congregate settings (eg, prisons or healthcare institutions), infection control and 
modification of the built environment can have a major impact in reducing transmission.
In prioritizing between different potential interventions in a given setting, creating 
“snapshots” of prevalent tuberculosis to understand who has active tuberculosis at a given 
time and how each case of infectious tuberculosis might have been averted can be helpful 
because these cases represent the tuberculosis transmission potential in a community. Novel 
study designs and statistical techniques (such as adaptive trials [53] and linkage of trial 
outcomes with transmission models [54]) can aid in developing an evidence base that speaks 
not just to the effectiveness of specific interventions but also to their comparative impact on 
transmission at the population level.
Although research to understand tuberculosis transmission is essential, we must link those 
efforts with rigorous evaluation of the efficacy and cost-effectiveness of transmission-halting 
interventions so that we can prioritize those activities most likely to prevent the greatest 
number of transmission events as rapidly as possible given available resources. Meanwhile, 
our armamentarium for halting tuberculosis transmission need not be limited to biomedical 
interventions. Historical data from Western Europe, where tuberculosis incidence declined 
10% annually after World War II, tells us that socioeconomic development can reduce 
tuberculosis transmission. We should hypothesize broadly about how socioeconomic 
development may interrupt transmission and systematically test interventions for impact, 
including nutrition support and direct cash transfer programs to household or individuals in 
tuberculosis-affected communities [55]. An additional benefit of interventions aimed at 
reducing tuberculosis transmission through poverty alleviation is that they may also reduce 
the spread of emerging infectious diseases such as pandemic influenza and Ebola. Finally, 
when evaluations to halt transmission do not turn out as expected, as with the Thibela 
tuberculosis trial of isoniazid preventive therapy in South African gold mines [12], rigorous 
efforts must be undertaken to understand the reasons behind the negative findings so that any 
pitfalls can be adequately addressed or avoided in future studies [54].
INTERRUPTING TRANSMISSION TO END TUBERCULOSIS
The global burden of tuberculosis cannot be understated. In addition to being the leading 
infectious disease killer and leading killer among people with HIV, the costs to healthcare 
systems, communities, families, and patients is unsustainable. For example, in Myanmar it is 
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estimated that 65% of tuberculosis- affected households face catastrophic costs (ie, >20% of 
their annual household income) [3]. The World Health Assembly member states have 
endorsed the END TB Strategy, which prioritizes intensified research and innovation. Here 
we propose that interrupting transmission become a central focus of that intensified research 
and innovation.
As we have described herein and in this series, measuring tuberculosis transmission in high-
burden settings where each case is not an isolated event represents a significant 
methodological challenge (Table 1). The dynamic interaction between the tuberculosis and 
HIV epidemics in many parts of the world further confounds this challenge. Addressing this 
challenge will require innovative, high-resolution tools, such as geospatial and whole 
genome sequencing–based analyses of transmission networks [56, 57]. Understanding who 
transmits to whom, where, and when using new molecular methods will inform the 
development, deployment, and assessment of precision public health interventions aimed at 
ending tuberculosis [58]. Countries can and should use such tools to “understand their 
epidemic” [59] in order to maximize the impact of current interventions and accelerate the 
application of new tools for the benefit of at-risk populations. For example, the recent 
decision of Public Health England to institute routine whole genome sequencing for all 
mycobacterial infections will undoubtedly contribute to advances in our understanding of 
transmission in the United Kingdom and other low-burden settings [60]. A deeper 
understanding of tuberculosis transmission may well lead to new interventions to interrupt it, 
as was the case for HIV with condoms, preexposure prophylaxis, and the dapivirine ring, for 
example.
The ongoing transmission of tuberculosis in clinics and hospitals is another area of grave 
concern that directly impacts patients, their families, and the global healthcare workforce. 
Tuberculosis has become an occupational lung disease for providers from high-burden 
countries, including frontline community health workers, nurses, medical students, and 
physicians [61–63]. Tuberculosis as a personal risk associated with a professional choice is 
unacceptable in the 21st century and must be addressed by national and international 
professional associations, lest their workers succumb to tuberculosis.
Ultimately, both established and new interventions will be required in order to end 
tuberculosis (Figure 1). Although established interventions such as isoniazid preventive 
therapy have been quite successful at reducing tuberculosis rates in many settings, several 
recent studies did not demonstrate a sustained impact for isoniazid preventive therapy in 
settings where transmission and force of infection is very high [6, 7, 9, 12, 64]. The same 
may be true for new interventions such as vaccines, which may protect against a single 
exposure or a low inoculum but be ineffective against repeated, high-dose exposures. The 
tuberculosis control community should therefore reduce ongoing transmission using all 
available methods such that any new tools can be effectively deployed. Only by combining 
the effective use of our existing tools with novel biomedical and social interventions will we 
be achieve the dramatic declines in incidence necessary to achieve our goals of tuberculosis 
elimination. And only then will we know that we have reached the end of our research 
roadmap for tuberculosis transmission science.
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In conclusion, continued research in basic discovery, clinical epidemiology, programmatic 
and population interventions, and cost-effectiveness are required to interrupt transmission 
and end tuberculosis. We hope that this series furthers that call by highlighting both the gaps 
and the enormous potential in transmission research. The success of the Global Plan and our 
collective ability to bend the curve of tuberculosis incidence to zero will require a concerted 
effort to interrupt transmission today.
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Figure 1. 
Projected acceleration in the decline of global tuberculosis incidence rates to target levels. 
From WHO END TB Strategy [62].
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Table 1
Tuberculosis Transmission Research Needs, Potential Obstacles, and Anticipated Impact and Benefit.
Research needs Potential obstacles
Anticipated impact and 
benefit
Infectiousness and susceptibility Aerobiology: variability in 
cough aerosol production, 
role of tidal breathing, 
airborne survival of Mtb 
particles
Heterogeneity among patients and 
limited tools for evaluating aerosol 
particles
Better tools for preventing 
aerosol transmission, 
particularly in nosocomial 
settings
Degree of source case 
infectiousness (eg, for 
subclinical disease, people 
with HIV)
Identification of people with 
subclinical disease prior to onset of 
symptoms
Understanding of relative 
contributions from different 
source cases and ability to 
target prevention efforts 
accordingly
Means to reduce effective 
contact rates and shared air
Cost and logistics of overhauling 
congregate facilities; need to engage 
nonmedical disciplines (eg, 
engineering, biotechnology)
Reduction of transmission 
in congregate settings
Correlates of resistance to 
tuberculosis infection
Inadequate animal models Vaccine to prevent infection
Drivers of transmission Local epidemiology and 
relative contribution of 
various factors in a given 
setting
Multidisciplinary approach needed to 
fully illustrate drivers and catalysts of 
transmission
Evidence to guide use of 
limited public health 
resources for targeted 
interventions
Better measures and markers 
of transmission
TST/IGRA does not differentiate 
recent from remote infection
Accurate measures of 
impact of interventions 
designed to halt 
transmission
Community locations of 
transmission
Difficult to identify epidemiologic 
links among casual contacts
Identification of congregate 
areas that may be driving 
nonhousehold transmission
Real-time molecular 
epidemiology and whole 
genome sequencing to 
identify linked cases
High cost and technical capacity for 
molecular epidemiology; transmission 
occurring from undiagnosed cases
Rapid recognition of 
outbreaks and potential to 
intervene and prevent 
further transmission
Interventions to halt tuberculosis 
transmission
Detailed cross-sectional 
snapshots of tuberculosis 
prevalence and transmission 
at the community level
Difficulty in identifying/diagnosing 
the tuberculosis cases most associated 
with transmission
Understanding the sources 
of tuberculosis transmission 
in communities (ie, who 
needs to be evaluated and 
diagnosed)
Models and decision aids to 
prioritize those interventions 
likely to have greatest impact 
on transmission in different 
settings
Assumptions needed for decision 
making in the absence of complete 
data
Ability to prioritize those 
interventions most likely to 
reduce transmission, given 
current resource availability
Clinical trials of 
interventions designed to halt 
tuberculosis transmission in 
populations
Need for preliminary evidence of 
ability to curb transmission at the 
population level
Novel evidence-based 
interventions proven to 
reduce population-level 
tuberculosis transmission
Abbreviations: HIV, human immunodeficiency virus; IGRA, interferon-gamma release assay; Mtb, Mycobacterium tuberculosis; TST, tuberculin 
skin test.
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